Detail akcie Illumina Inc online

Business Summary: Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Financial Summary: BRIEF: For the six months ended 29 June 2025, Illumina Inc revenues decreased 4% to $2.1B. Net income totaled $366M vs. loss of $2.11B. Revenues reflect Americas segment decrease of 7% to $1.16B, Asia, Middle East, and Africa segment decrease of 8% to $206M. Net Income reflects Goodwill and intangible impairment decrease from $1.89B (expense) to $0K, Other expense, net - Balancing value increase from $328M (expense) to $131M (income).